StockMarketWire.com - AstraZeneca's partner FibroGen Tuesday received marketing authorisation from the China National Medical Products Administration for its new oral drug to treat patients with anaemia caused by chronic kidney disease.

Anaemia caused by chronic kidney disease was associated with cardiovascular disease, hospitalisation, cognitive impairment and reduced quality of life, and had been shown consistently to increase the risk of death in patients, the company said.

Fibrogen's anaemic treatment, Roxadustat, was approved following an open-label, active-control 26-week Phase III trial in dialysis dependent-chronic-kidney-disease patients with anaemia who were previously treated with various forms of a generic erythropoiesis-stimulating agent.

'Roxadustat is a long-awaited, first-in-class medicine for patients with anaemia in chronic kidney disease that are on dialysis. This first approval of roxadustat in China is a significant step towards achieving our ambition to transform care in a condition where prevalence in China is increasing,' said Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer.


At 9:54am: [LON:AZN] AstraZeneca PLC share price was -52p at 5991p



Story provided by StockMarketWire.com